|
rs121913273
|
|
|
0.010 |
GeneticVariation |
BEFREE |
A nonsense mutation in PTPN11 (K99X), a pathogenic CCND1 splice site variant (P241P), a hotspot missense mutation in PIK3CA (E542K) and a hotspot missense mutation in TP53 (R249S); were observed in 25%, 75%, 30% and 40% of the HER2+ BC tissue samples, respectively.
|
30535550 |
2019 |
|
rs186919241
|
|
|
0.010 |
GeneticVariation |
BEFREE |
A nonsense mutation in PTPN11 (K99X), a pathogenic CCND1 splice site variant (P241P), a hotspot missense mutation in PIK3CA (E542K) and a hotspot missense mutation in TP53 (R249S); were observed in 25%, 75%, 30% and 40% of the HER2+ BC tissue samples, respectively.
|
30535550 |
2019 |
|
rs28933368
|
|
|
0.010 |
GeneticVariation |
BEFREE |
A nonsense mutation in PTPN11 (K99X), a pathogenic CCND1 splice site variant (P241P), a hotspot missense mutation in PIK3CA (E542K) and a hotspot missense mutation in TP53 (R249S); were observed in 25%, 75%, 30% and 40% of the HER2+ BC tissue samples, respectively.
|
30535550 |
2019 |
|
rs28934571
|
|
|
0.010 |
GeneticVariation |
BEFREE |
A nonsense mutation in PTPN11 (K99X), a pathogenic CCND1 splice site variant (P241P), a hotspot missense mutation in PIK3CA (E542K) and a hotspot missense mutation in TP53 (R249S); were observed in 25%, 75%, 30% and 40% of the HER2+ BC tissue samples, respectively.
|
30535550 |
2019 |
|
rs387907158
|
|
|
0.010 |
GeneticVariation |
BEFREE |
A nonsense mutation in PTPN11 (K99X), a pathogenic CCND1 splice site variant (P241P), a hotspot missense mutation in PIK3CA (E542K) and a hotspot missense mutation in TP53 (R249S); were observed in 25%, 75%, 30% and 40% of the HER2+ BC tissue samples, respectively.
|
30535550 |
2019 |
|
rs1442481831
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Of these, two mutations, the somatic mutations <i>ERBB4</i>-V721I and <i>ERBB4</i>-S303F, were stably transfected into HCC1954 (PIK3CA mutant), HCC1569 (PIK3CA wildtype) and BT474 (PIK3CA mutant, ER positive) HER2+ breast cancer cell lines for functional <i>in vitro</i> experiments.
|
30023006 |
2018 |
|
rs1484791833
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Of these, two mutations, the somatic mutations <i>ERBB4</i>-V721I and <i>ERBB4</i>-S303F, were stably transfected into HCC1954 (PIK3CA mutant), HCC1569 (PIK3CA wildtype) and BT474 (PIK3CA mutant, ER positive) HER2+ breast cancer cell lines for functional <i>in vitro</i> experiments.
|
30023006 |
2018 |
|
rs1058808
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The results of the present study suggest that patients with HER2-negative breast cancer with the HER2 Pro1170Ala polymorphism variant exhibit a decreased survival outcome.
|
28529593 |
2017 |
|
rs1799864
|
|
|
0.010 |
GeneticVariation |
BEFREE |
CCR2-V64I genetic polymorphism: a possible involvement in HER2+ breast cancer.
|
25716470 |
2016 |
|
rs2016347
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Additionally, we found a SNP (rs2016347) in IGF1R as a potential predictive marker for chemotherapy efficacy in BC patients treated with TAC.
|
26738606 |
2016 |
|
rs759478535
|
|
|
0.010 |
GeneticVariation |
BEFREE |
CCR2-V64I genetic polymorphism: a possible involvement in HER2+ breast cancer.
|
25716470 |
2016 |
|
rs763059810
|
|
|
0.010 |
GeneticVariation |
BEFREE |
CCR2-V64I genetic polymorphism: a possible involvement in HER2+ breast cancer.
|
25716470 |
2016 |
|
rs1057519803
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Whole-exome sequencing of the primary HER2-negative breast cancer and its HER2-negative synchronous liver metastasis from a 46-year-old female revealed the presence of an activating and clonal HER3 G284R mutation.
|
25953157 |
2015 |
|
rs10825036
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In the two-stage GWAS stratified by tumor subtypes, rs166870 and rs10825036 were consistently associated with DFS in the HR+ HER2- and HR- HER2- breast cancer subtypes, respectively (Prs166870 = 2.88 × 10(-7) and Prs10825036 = 3.54 × 10(-7) in the combined set).
|
25867717 |
2015 |
|
rs166870
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In the two-stage GWAS stratified by tumor subtypes, rs166870 and rs10825036 were consistently associated with DFS in the HR+ HER2- and HR- HER2- breast cancer subtypes, respectively (Prs166870 = 2.88 × 10(-7) and Prs10825036 = 3.54 × 10(-7) in the combined set).
|
25867717 |
2015 |
|
rs758204762
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Whole-exome sequencing of the primary HER2-negative breast cancer and its HER2-negative synchronous liver metastasis from a 46-year-old female revealed the presence of an activating and clonal HER3 G284R mutation.
|
25953157 |
2015 |
|
rs1136201
|
|
|
0.010 |
GeneticVariation |
BEFREE |
At a median follow-up of 44 months, HER2 Ile655Val polymorphism was not significantly associated with survival either in the entire study population of 4167 patients or in 2976 HER2-negative breast cancer patients.
|
24608202 |
2014 |
|
rs8170
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Variants from 19p13.1 were not associated with breast cancer overall or with ER-positive breast cancer but were significantly associated with ER-negative breast cancer risk [rs8170 OR, 1.10; 95% confidence interval (CI), 1.05-1.15; P = 3.49 × 10(-5)] and triple-negative (ER-, PR-, and HER2-negative) breast cancer (rs8170: OR, 1.22; 95% CI, 1.13-1.31; P = 2.22 × 10(-7)).
|
22331459 |
2012 |